醫師學術論文
Paper高榮達 Jung-Ta Kao 主治醫師
高榮達醫師為中國醫藥大學臨床醫學博士,擅長於病毒性肝炎、肝硬化、肝癌的診斷與治療。肝癌是台灣最常見的癌症之一,其好發年齡層在 60-70 歲,發生肝癌的危險因子包括:B型或C型肝炎感染、長時間酒精攝取、家族肝癌史等。肝癌診斷方法包括:肝臟超音波、電腦斷層檢查、血管攝影等、血中胎兒蛋白值檢驗。高醫師亦擅長於肝腫瘤細針穿刺檢查、腹部超音波檢查、消化道內視鏡檢查(胃鏡、大腸鏡)。
分院掛號
學術機構典藏
論文
期刊論文
期刊論文/Journal Paper (作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄) |
日期 | |
1 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、彭成元(Peng, Cheng-Yuan)*,Liver stiffness and spleen stiffness predict distinct liver-related events after hepatitis C eradication with direct-acting antivirals,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2024 Dec,123(12):1279-1286 | 2024 . 12 |
2 | 王鴻偉(Hung-Wei Wang)、賴學洲(Hsueh-Chou Lai)*、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、陳浤燿(Hung-Yao Chen)、張哲維(Che-Wei Chang)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*,Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma,Journal of Gastrointestinal Oncology,2024 Sep,0(0):0-0 | 2024 . 09 |
3 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、陳政國(Cheng-Kuo Chen)、王鴻偉(Hung-Wei Wang)、莊伯恒(Po-Heng Chuang)、蔡明宏(Ming-Hung Tsai)、陳昇弘(Chen, Sheng-Hung)、朱家聲(Chia-Sheng Chu)、蘇文邦(Wen-Pang Su)、周仁偉(Jen-Wei Chou)、高榮達(Jung-Ta Kao)、陳浤燿(Hung-Yao Chen)、莊世杰(Shih-Chieh Chuang)、蔡宗佑(Tsung-Yu Tsai)、蕭望德(Won-Der Shau)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*,Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy,American Journal of Cancer Research,2023 Feb,13(2):654-668 | 2023 . 02 |
4 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、謝宗霖(Tsung-Lin, Hsieh)、陳浤燿(Hung-Yao Chen)、彭成元(Peng, Cheng-Yuan)*,Combined Liver Stiffness and Α-fetoprotein further beyond the Sustained Virologic Response Visit as Predictors of Long-term Liver-related Events in Patients With Chronic Hepatitis C,Canadian Journal of Gastroenterology and Hepatology,2022 Jul,2022():5201443-5201443 | 2022 . 07 |
5 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、蔡宗佑(Tsung-Yu Tsai)、陳浤燿(Hung-Yao Chen)、彭成元(Cheng-Yuan Peng)*,Liver and spleen stiffness surveillance through elastography during and after direct-acting antiviral therapy in patients with chronic hepatitis C,JOURNAL OF ULTRASOUND IN MEDICINE,2022 Apr,41(5):1169-1177 | 2022 . 04 |
6 | 謝明翰(Hsieh, Ming-Han)、高子淯(Tzu-Yu Kao)、謝婷卉(Ting-Hui Hsieh)、高群棋(Chun-Chi Kao)、彭成元(Peng, Cheng-Yuan)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、高榮達(Jung-Ta Kao)*,Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study,Therapeutic Advances in Chronic Disease,2021 Dec,(): | 2021 . 12 |
7 | 王鴻偉(Hung-Wei Wang)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)*,On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma,Cancers,2021 Jul,13(15):3758 | 2021 . 07 |
8 | 謝明翰(Hsieh, Ming-Han)、高子淯(Tzu-Yu Kao)、謝婷卉(Ting-Hui Hsieh)、高群棋(Chun-Chi Kao)、彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、(Chuang PH)、高榮達(Jung-Ta Kao)*,Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib,PLoS One,2020 Dec,15(12):e0244293 | 2020 . 12 |
9 | 陳政國(Cheng-Kuo Chen)、馮俊龍(Chun-Lung Feng)、余承儒(Cheng-Ju Yu)、彭成元(Peng, Cheng-Yuan)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、林宜靜(Yi-Ching Lin)、黃文信(Wen-Hsin Huang)、高榮達(Jung-Ta Kao)*,Prognostic factors associated with the survival of patients : A retrospective study,Advances in Digestive Medicine,2020 Jul,7():68-76 | 2020 . 07 |
10 | 陳昇弘(Sheng-Hung Chen)、賴學洲(Hsueh-Chou Lai)、江宜平(I-Ping Chiang)、蘇文邦(Wen-Pang Su)、林佳欣(Chia-Hsin Lin)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、黃冠棠(Guan-Tarn Huang)、彭成元(Cheng-Yuan Peng)*,Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients With Chronic Hepatitis C After Viral Eradication,CLINICAL INFECTIOUS DISEASES,2020 Jan,70(1):114-122 | 2020 . 01 |
11 | 朱家聲(Chia-Sheng Chu)、彭成元(Cheng-Yuan Peng)、江宜平(I-Ping Chiang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、黃文信(Wen-Hsin Huang)、賴學洲(Hsueh-Chou Lai)*,Endoscopic findings in a patient with primary malignant melanoma of the esophagus: A case report,Advances in Digestive Medicine,2019 May,2019():1-4 | 2019 . 05 |
12 | 吳怡瑩*、(CHIN-TUNG HSIEH)、蔡嘉哲(Jia-Zer Tsay)、高榮達(Jung-Ta Kao)、(Ying?Ming Chiu)*、(Dong?Chen Shieh)、(Yi?Ju Lee),Recruitment of CCR6+ Foxp3+ regulatory gastric infiltrating lymphocytes in Helicobacter pylori gastritis.,HELICOBACTER,2019 Feb,24(1): | 2019 . 02 |
13 | 蔡淑美(Tsai Shu-Mei)、高榮達(Jung-Ta Kao)、蔡芸芳(Tsai Yung-Fang)*,Illness trajectory of initial infection for hepatitis C patients: A Qualitative Study,Nursing & Health Sciences,2019 Jan,21(1):112-118 | 2019 . 01 |
14 | (YING-MING CHIU)、(CHUNG-LIN TSAI)、高榮達(Kao, Jung-Ta)、(CHIN-TUNG HSIEH)、(DONG-CHEN SHIEH)、(YI-JU LEE)、蔡嘉哲(Tsay, Gregory J)、鄭庚申(Cheng, Ken-Sheng)、吳怡瑩(Wu, Yi-Ying)*,PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma,ANTICANCER RESEARCH,2018 Apr,38(4):2069-2078 | 2018 . 04 |
15 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Lai, Hsueh-Chou)、江宜平(Chiang, I-Ping)、蘇文邦(Wen-Pang Su)、林佳欣、高榮達(Kao, Jung-Ta)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Chen, Ching-Hsiang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*,Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C,PLoS One,2018 Jan,13(1):e0190455-e0190455 | 2018 . 01 |
16 | (Mei-Hsuan Lee)*、(Chung-Feng Huang)、賴學洲(Hsueh-Chou Lai)、(Chun-Yen Lin)、(Chia-Yen Dia)、(Chun-Jen Liu)、(Jing-Houng Wang)、(Jee-Fu Huang)、蘇文邦(Wen-Pang Su)、(Hung-Chih Yang)、(Kwong-Ming Kee)、(Ming-Lun Yeh)、莊伯恒(Po-Heng Chuang)、Shih-Jer Hsu、(Ching-I Huang)、高榮達(Jung-Ta Kao)、(Chieh-Chang Chen)、陳昇弘(Sheng-Hung Chen)、(Wen-Juei Jeng)、(Hwai-I Yang)、(Yong Yuan)、(Sheng-Nan Lu)*、(I-Shyan Sheen)*、(Chen-Hua Liu)*、彭成元(Cheng-Yuan Peng)*、(Jia-Horng Kao)*、(Ming-Lung Yu)*、(Wan-Long Chuang)*、(Chien-Jen Chen)*,Clinical efficacy and post-treatment seromarkers associated with the risk of hepatocellular carcinoma among chronic hepatitis C patients,Scientific Reports,2017 Jun,7(1):3718-3718 | 2017 . 06 |
17 | 高榮達(Jung-Ta Kao)、余承儒(Cheng-Ju Yu)、馮俊龍(Chun-Lung Feng)、(Shu-Mei Tsai)、(Yao-Li Chen)*、吳怡瑩(WU YI-YING)*,IL-6 significantly correlates with p-STAT3 expression and presents high variceal bleeding with mortality in cirrhotic patients: a cross-sectional study,JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION,2017 Jun,50(3):286-296 | 2017 . 06 |
18 | 陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*、江宜平(I-Ping Chiang)、賴學洲(Hsueh-Chou Lai)、李瓊如(Chiung-Ju Lee)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang),Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C.,MEDICINE,2016 Aug,95(35):e4736-e4736 | 2016 . 08 |
19 | (Tsai, Shu-Mei)、高榮達(Jung-Ta Kao)*、(Tsai, Yun-Fang),How Hepatitis C Patients Manage the Treatment Process of Pegylated Interferon and Ribavirin Therapy: A Qualitative Study,BMC HEALTH SERVICES RESEARCH,2016 Jul,16():247 | 2016 . 07 |
20 | 蕭望德(Won-Der Shau)、彭成元(Cheng-Yuan Peng)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、周仁偉(Jen-Wei Chou)、陳洋源(Yang-Yuan Chen)、余承儒(Cheng-Ju Yu)、馮俊龍(Chun-Lung Feng)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、高榮達(Jung-Ta Kao)*,Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study,BMC GASTROENTEROLOGY,2016 Apr,.(.): | 2016 . 04 |
21 | 丁俊夫(Chun-Fu Ting)、高榮達(Jung-Ta Kao)*、黃文信(Wen-Hsin Huang)、馮俊龍(Chun-Lung Feng)、余承儒(Cheng-Ju Yu)、彭成元(Cheng-Yuan Peng)、蘇文邦(Wen-Pang Su)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、莊伯恒(Po-Heng Chuang),Clinical factors associated with the survival of patients with intrahepatic cholangiocarcinoma,Advances in Digestive Medicine,2016 Mar,(): | 2016 . 03 |
22 | 陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、江宜平(I-Ping Chiang)、李瓊如、蘇文邦(Wen-Pang Su)、林佳欣、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang),Head-to-Head Comparison between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Quantification in Chronic Hepatitis C,PLoS One,2015 Oct,10(10):e0140554-e0140554 | 2015 . 10 |
23 | 高榮達(Jung-Ta Kao)、馮俊龍(Chun-Lung Feng)、余承儒(Cheng-Ju Yu)、(Shu-Mei Tsai)、(Ping-Ning Hsu)、(Yao-Li Chen)*、吳怡瑩(WU YI-YING)*,IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study,BMC GASTROENTEROLOGY,2015 Apr,25(15):50 | 2015 . 04 |
24 | 賴學洲(Hsueh-Chou Lai)、林則成(Che-Chen Lin,)、鄭庚申(Ken-Sheng Cheng)、高榮達(Jung-Ta Kao)、周仁偉(Jen-Wei Chou)、彭成元(Cheng-Yuan Peng)、賴世偉(Shih-Wei Lai)、陳培君(Pei-Chun Chen)*、宋鴻樟(Fung-Chang Sung)*,Increased Incidence of Gastrointestinal Cancers Among Patients With Pyogenic Liver Abscess: A Population-Based Cohort Study,Gastroenterology,2014 Jan,146(1):129-137 | 2014 . 01 |
25 | 陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、林佳欣(Chia-Hsin Lin)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、林志明(Chih-Ming Lin)、陳景祥(Ching-Hsiang Chen),THE ASSOCIATION BETWEEN SINGLE-NUCLEOTIDE POLYMORPHISMS IN THE INOSINE TRIPHOSPHATE PYROPHOSPHATASE GENE AND RIBAVIRIN (RBV)-INDUCED HEMOLYTIC ANEMIA IN GENOTYPE 2 HEPATITIS C VIRUS-INFECTED TAIWANESE PATIENTS RECEIVING PEGYLATED INTERFERON AND RBV COMBIN,臺灣消化醫學雜誌,2013 Sep,30(3):256-266 | 2013 . 09 |
26 | 陳昇弘(Sheng-Hung Chen)、李郁芬(Yu-Fen Li)、賴學洲(Hsueh-Chou Lai)、高榮達(Jung-Ta Kao)、彭成元(Cheng-Yuan Peng)*、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、江宜平(I-Ping Chiang),Noninvasive Assessment of Liver Fibrosis via Spleen Stiffness Measurement using Acoustic Radiation Force Impulse Sonoelastography in Patients with Chronic Hepatitis B or C,JOURNAL OF VIRAL HEPATITIS,2012 Sep,19(9):654-663 | 2012 . 09 |
27 | 陳昇弘(Sheng-Hung Chen)、李郁芬(Yu-Fen Li)、賴學洲(Hsueh-Chou Lai)、高榮達(Jung-Ta Kao)、彭成元(Cheng-Yuan Peng)*、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、江宜平(I-Ping Chiang),Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C,BMC GASTROENTEROLOGY,2012 Aug,12(1):105-105 | 2012 . 08 |
28 | 高榮達(Jung-Ta Kao)、賴學洲(Hsueh-Chou Lai)、蔡淑美(Shu-Mei Tsai)、林佩昭(Pei-Chao Lin)、莊伯恒(Po-Heng Chuang)、余承儒(Cheng-Ju Yu)、鄭庚申(Ken-Sheng Cheng)、蘇文邦(Wen-Pang Su)、許秉寧(Ping-Ning Hsu)、彭成元(Cheng-Yuan Peng)、吳怡瑩(WU YI-YING)*,Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naı¨ve hepatitis B infection patients,LIVER INTERNATIONAL,2012 Jul,32(6):928-936 | 2012 . 07 |
29 | 彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、李郁芬(Yu-Fen Li)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、高榮達(Jung-Ta Kao),Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B,ALIMENTARY PHARMACOLOGY & THERAPEUTICS,2012 Feb,35(4):458-468 | 2012 . 02 |
30 | 高榮達(Jung-Ta Kao)、(Chung-Mou Kuo)、(Yi-Chun Chiu)、(Chi-Sin Changchien)、(Chung-Huang Kuo)*,Congenital anomaly of low insertion of cystic duct: endoscopic retrograde cholangiopancreatography findings and clinical significance.,JOURNAL OF CLINICAL GASTROENTEROLOGY,2011 Aug,45(): | 2011 . 08 |
31 | 吳怡瑩(WU YI-YING)*、陳俊宏(Jiunn-Horng Chen)、高榮達(Jung-Ta Kao)、劉國慶(KUO-CHING LIU)、賴志河(Chih-Ho Lai)、王淵民(Yuan-Min Wang)、謝錦桐(Chin-Tung Hsieh)、曾志正(Jason T. C. Tzen)、許秉寧(Ping-Ning Hsu),Expression of CD25high Regulatory T Cells and PD-1 in Gastric Infiltrating CD4+ T Lymphocytes in Patients with Helicobacter pylori Infection,Clinical and Vaccine Immunology,2011 Jul,18(7):1198-1201 | 2011 . 07 |
32 | 王淵民(Yuan-Min Wang)、陸自利、(Ping-Ning Hsu)、湯智昕(Tang Chih-Hsin)、陳俊宏(Jiunn-Horng Chen)、高榮達(Jung-Ta Kao)、(Jason T.C. Tzen)、吳怡瑩(WU YI-YING)*,Ribosome inactivating protein B-chain induces osteoclast differentiation from monocyte/macrophage lineage precursor cells,BONE,2011 Feb,(): | 2011 . 02 |
33 | 許秉寧、楊翠青(Tsuey-Ching Yang)、高榮達(Jung-Ta Kao)、鄭庚申(Ken-Sheng Cheng)、(Yi-Ju Lee)、(Yuan-Min Wang)、(Chin-Tung Hsieh)、林振文(Lin Cheng Wen)、吳怡瑩(WU YI-YING)*,Increased PD-1and decreased CD28 expression in chronic hepatitis B patientswith advanced hepatocellular carcinoma,LIVER INTERNATIONAL,2010 Oct,30(9):1379-1386 | 2010 . 10 |
34 | 高榮達(Jung-Ta Kao)、(Jing-Houng Wang)、(Chao-Hung Hung)、(Yi-Hao Yen)、(Shu-Fen Hung)、(Tsung-Hui Hu)、(Chuan-Mo Lee)、(Sheng-Nan Lu)*,Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan,Vaccine,2009 Mar,27(12):1858-1862 | 2009 . 03 |
35 | 高榮達(Jung-Ta Kao)、盧勝男(Sheng-Nan Lu)*,Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination,LIVER INTERNATIONAL,2008 Nov,28(9):1298-1304 | 2008 . 11 |
36 | 高榮達(Jung-Ta Kao),P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection,LIVER INTERNATIONAL,2007 Aug,27(6):772-781 | 2007 . 08 |
研討會論文
研討會論文/Conference Papers (發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目) |
日期 | |
1 | Risk Stratification for Hepatocellular Carcinoma after Hepatitis C Cure using Metabolic and Fibrotic Biomarkers,APASL (The Asian Pacific Association for the Study of the Liver) STC on MAFLD 2024,Kaohsiung,2024.06.29~2024.06.30, | 2024 . 06 |
2 | The Utility of Diabetes Mellitus Diagnosis and Post-Sustained Virologic Response Liver Stiffness Values in Predicting the Risk of Post-SVR Hepatocellular Carcinoma in Patients with Chronic Hepatitis C 慢性C型肝炎患者糖尿病診斷和持續病毒學反應後肝硬度值在預測持續病毒學反應後肝細胞癌風險中的意義和效用,Taiwan Digestive Disease Week 2023,National Sun Yat-sen University, Kaohsiung,2023.09.23~2023.09.24, | 2023 . 09 |
3 | The von Willebrand factor/platelet ratio as a surrogate biomarker of spleen stiffness measurement in patients with chronic hepatitis C after antiviral treatment,中華民國112 年消化系聯合學術演講年會 TDDW 2023,台北榮民總醫院,2023.03.25~2023.03.26, | 2023 . 03 |
4 | HIF-1α 的過度表現激活肝功能障礙並影響肝癌患者的生存:一個橫斷面研究,台灣內科醫學會111年會員大會暨學術演講會,台大醫院國際會議中心,2022.12.3 ~2022.12.4 , | 2022 . 12 |
5 | ALBI grade: a predictor of treatment response and outcome for patients with unresectable hepatocellular carcinoma receiving sorafenib-regorafenib sequential therapy,中華民國一一O年台灣消化系聯合學術演講年會,中國醫藥大學英才校區,2021.03.27~2021.03.28, | 2021 . 03 |
6 | 周產期及停經後的婦女患有原發性肝惡性腫瘤有較差的預後嗎?來自台灣全國性的世代研究證據,中華民國110年消化系聯合學術演講年會,中國醫藥大學,2021.03.27~2021.03.28, | 2021 . 03 |
7 | Direct-acting antiviral therapies in patients with HIV/HCV coinfection,2021台灣消化系聯合學術演講年會,中國醫藥大學,2021.03.27~2021.03.28, | 2021 . 03 |
8 | Factors predicting liver histological changes under long-term follow-up chronic hepatitis C patients treated with pegylated-interferon-alpha plus ribavirin,The Digital International Liver Congress,倫敦,2020.08.27~2020.08.29, | 2020 . 08 |
9 | ,2019 International Education Symposium in HCC: Rapid Evolution of HCC Treatment,Taichung,2019.12.01~2019.12.01,Target therapies in advanced HCC:Optimizing outcomes with sequential treatment | 2019 . 12 |
10 | Impacts of Diabetes and Hypertension on Hepatocellular Carcinoma Patients Receiving Sorafenib,The 10th Asia Pacific Primary Liver Cancer Expert Meeting,Sapporo,2019.08.29~2019.08.31, | 2019 . 08 |
11 | Impacts of Diabetes and Hypertension on Hepatocellular Carcinoma Patients Receiving Sorafenib,The 10th Asia Pacific Primary Liver Cancer Expert Meeting,Sapporp,2019.08.29~2019.08.31, | 2019 . 08 |
12 | ,Management of Chronic Hepatitis B: strategies for the burden and barrier.,台南,2018.08.25~2018.08.25,Geniric experience for HBV treatment | 2018 . 08 |
13 | Significant Annual Declines in Liver Stiffness on Acoustic Radiation Force-Impulse Elastography Over Five-year Surveillances in Patients Treated with Antiviral Nucleos(t)ide Analogs for Chronic Hepatitis B,2017 Taiwan Digestive Disease Week,NTUH International Convention Center, Taipei,2017.09.30~2017.10.01, | 2017 . 09 |
14 | ,BIT's10th Annual World Cancer Congress,Barcelona,2017.05.19~2017.05.21,Molecular Study in Hepatocellular Carcinoma Patients | 2017 . 05 |
15 | Over-expression of HIF-1α activates liver dysfunction and affects survival of hepatoma patients a cross sectional study,中華民國一○六年消化系聯合學術演講年會,台中榮民總醫院,2017.03.18~2017.03.19, | 2017 . 03 |
16 | ARFI肝臟硬度測試是否可做為預測以DAA等治療慢性C型肝炎之病毒學反應的顯著預測因子?Real-world Experiences,106年台灣消化系聯合學術演講年會,台中榮民總醫院,2017.03.17~2017.03.19,ARFI肝臟硬度測試是否可做為預測以DAA等治療慢性C型肝炎之病毒學反應的顯著預測因子?Real-world Experiences | 2017 . 03 |
17 | Sorafenib For Advanced Stage HCC : Real Life Practice Analysis in Single Medical Center,中華民國一○五年消化系聯合學術演講年會,臺北榮民總醫院致德樓第三會議室,2016.03.26~2016.03.27, | 2016 . 03 |
18 | Head-to-head Comparisons between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Evaluation,The Liver Week 2015,Busan, Republic of Korea,2015.09.10~2015.09.12, | 2015 . 09 |
19 | Sorafenib Combined with Transarterial Chemoembolization or Radiation Therapy Versus Sorafenib Alone For Advanced Stage Hepatocellular Carcinoma –A Daily Practice Analysis,8th Annual Conference of the International Liver Cancer Association (ILCA), 2014,Hotel Granvia Kyoto in Japan,2014.09.05~2014.09.07, | 2014 . 09 |
20 | Diagnostic index for advanced liver fibrosis in Asian chronic hepatitis B patients based on necroinflammation and liver stiffness measurement,The Liver Meeting 2013, AASLD,Washington, USA,2013.11.03~2013.11.04,Diagnostic index for advanced liver fibrosis in Asian chronic hepatitis B patients based on necroinflammation and liver stiffness measurement, published in Hepatology 2013; Special Issue: The Liver Meeting 2013; 58(S1):122A | 2013 . 11 |
21 | A Predictive Index using the Inosine Triphosphate Pyrophosphatase Gene Allele Status to Predict Ribavirin-induced Hemolytic Anemia in Genotype 1 Hepatitis C Virus-infected Asian Patients Receiving Pegylated Interferon and Ribavirin Combination Therapy,Taiwan Digestive Disease Week, 2013,Taipei, Taiwan,2013.10.04~2013.10.06, | 2013 . 10 |
22 | Predictive role of serum HBsAg level in genotype B or C HBeAg-negative chronic hepatitis B patients undergoing peginterferon therapy.,48th Annual Meeting of the European Association for the Study of the Liver,Amsterdam, the Netherlands,2013.04.24~2013.04.28, | 2013 . 04 |
23 | Predictive role of quantitative serum HBsAg level in HBeAg-negative chronic hepatitis B patients undergoing peginterferon therapy,中華民國102年台灣消化系聯合學術演講年會,高雄醫學大學,2013.03.16~2013.03.17, | 2013 . 03 |
24 | ,台灣消化系醫學會暨台灣消化系內視鏡醫學會聯合學術演講年會,高雄醫學大學,2013.03.16~2013.03.17, | 2013 . 03 |
25 | Evaluation of Decompensated Cirrhosis using Acoustic Radiation Force Impulse Elastography: comparisons with Child-Pugh and model for end-stage liver disease scores,中華民國102年台灣消化系聯合學術演講年會,高雄醫學大學,2013.03.15~2013.03.17, | 2013 . 03 |
26 | Necroinflammatory effects on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in Asian patients with chronic hepatitis B,中華民國101年消化系聯合學術演講年會 Taiwan Digestive Disease Week,國防醫學中心,2012.10.05~2012.10.07, | 2012 . 10 |
27 | Predictors of Serum HBsAg Decline in Chronic Hepatitis B Patients Undergoing Entecavir Therapy,中華民國101年消化系聯合學術演講年會,台北國防醫學中心,2012.03.23~2012.03.25, | 2012 . 03 |
28 | RFA immediately after PEI for treating HCC might increase the risk of delayed pyogenic liver abscess,The 22nd Congress of the Asian Pacific Association for the Study of the Liver (APASL 2012),Taipei International Convention Center,2012.02.16~2012.02.19, | 2012 . 02 |
29 | NONINVASIVE ASSESSMENT OF LIVER FIBROSIS VIA SPLEEN STIFFNESS MEASUREMENT USING ACOUSTIC RADIATION FORCE IMPULSE SONOELASTOGRAPHY IN PATIENTS WITH CHRONIC HEPATITIS B OR C,22nd Congress of the Asian Pacific Association for the Study of the Liver (APASL 2012),The Taipei International Convention Center,2012.02.17~2012.02.19, | 2012 . 02 |
30 | Predictors of Development of HBeAg-Negative Chronic Hepatitis B Following Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B,The 62nd Annual Meeting of the American Association for the Study of Liver Diseases,San Francisco, CA, USA,2011.11.04~2011.11.08, | 2011 . 11 |
31 | 以聲脈衝幅射力技術預測C型肝炎病人肝纖維化分級之效度分析,Taiwan Digestive Disease Week (TDDW) 2011 中華民國100年消化系聯合學術演講年會,國防醫學中心,2011.10.07~2011.10.10, | 2011 . 10 |
32 | Predictors of Development of HBeAg-Negative Chronic Hepatitis B Following Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B,Taiwan Digestive Disease Week (TDDW) 2011 中華民國100年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.10.08~2011.10.10, | 2011 . 10 |
33 | PREDICTORS OF THERAPEUTIC RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.03.05~2011.03.06, | 2011 . 03 |
34 | EFFECT OF IMPACTED AMPULLARY STONES ON THE SEVERITY OF GALLSTONE DISEASES,中華民國一○○年消化系聯合學術演講年會,國防醫學中心,2011.03.04~2011.03.06, | 2011 . 03 |
35 | PEGYLATED INTERFERON-ASSOCIATED LIFE-THREATENING UPPER GASTROINTESTINAL BLEEDING IN UREMIC PATIENTS WITH CHRONIC HEPATITIS C,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.03.05~2011.03.06, | 2011 . 03 |
36 | 超音波導引經皮肝臟及肝腫塊穿刺切片之併發症:一醫學中心之六年報告,中華民國100年消化系聯合學術演講年會春季會,國防醫學中心,2011.03.05~2011.03.06, | 2011 . 03 |
37 | ARE METABOLIC PARAMETERS ASSOCIATED WITH VIROLOGIC RESPONSE TO PEGINTERFERON ALFA PLUS RIBAVIRIN THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C:A SINGLE CENTER EXPERIENCE,中華民國100年臺灣消化系醫學會春季學術演講年會,臺北市內湖區國防醫學中心,2011.03.04~2011.03.05, | 2011 . 03 |
38 | Time Trends of Gastroesophageal Reflux Disease, Esophageal Cancer, Gastric Cancer, and Peptic Ulcer Disease in Taiwan 2000 to 2008 - a population based study,中華民國100年消化系聯合學術演講年會,國防醫學中心,2011.03.05~2011.03.06, | 2011 . 03 |
39 | INTERLEUKIN-27 (IL-27)在B/C型肝炎病人的角色,中華民國一00年消化系聯合學術演講年會,台北喜來登飯店B2福祿廳,2011.03.05~2011.03.06, | 2011 . 03 |
40 | Kinetics of serum HBsAg and HBV DNA levels during peginterferon alfa-2A therapy in patients with HBeAg-positive chronic hepatitis B: genotype B versus C,中華民國九十九年臺灣消化系醫學會秋季學術演講年會,臺北市內湖區國防醫學中心,2010.10.01~2010.10.03, | 2010 . 10 |
41 | ALT flares and their relation with HBeAg loss during peginterferonα-2A theapy in patients with HBeAg-positive chronic hepatitis B,中華民國九十九年臺灣消化系醫學會秋季學術演講年會,臺北市內湖區國防醫學中心,2010.10.01~2010.10.03, | 2010 . 10 |
42 | C型肝炎患者於抗病毒藥物治療後達到病毒持續反應的預測因子,2010消化系聯合學術演講年會,三軍總醫院,2010.03.20~2010.03.21, | 2010 . 03 |
43 | 探尋評估慢性B型肝炎纖維化的非侵入性指標,尚待發掘的指標存在嗎?,2010消化系聯合學術演講年會,三軍總醫院,2010.03.20~2010.03.21, | 2010 . 03 |
44 | Changes in Serum Triglyceride Levels in Patients with Chronic Hepatitis C and Patients with Chronic Hepatitis B Undergoing Peginterferon-Based Therapy:a single center experience,中華民國九十九年消化系聯合學術演講年會,國防醫學中心(台北市民權東路六段 161 號),2010.03.20~2010.03.21,Changes in Serum Triglyceride Levels in Patients with Chronic Hepatitis C and Patients with Chronic Hepatitis B Undergoing Peginterferon-Based Therapy:a single center experience | 2010 . 03 |
45 | 長效型干擾素ALFA-2A在E抗原陽性之慢性B型肝炎療效分析,2010消化系聯合學術演講年會,三軍總醫院,2010.03.20~2010.03.21, | 2010 . 03 |
46 | Efficacy of entecavir in naive patients with chronic hepatitis B and decompensated liver cirrhosis,Asian Pacific Digestive Week,Taipei International Convention Center, Taipei, Taiwan,2009.09.27~2009.09.30, | 2009 . 09 |
47 | Pegylated interferon alfa-2a therapy for HBeAg-negative chronic hepatitis B in Taiwan,Asian Pacific Digestive Week,Taipei International ConventionCenter,Taipei,Taiwan,2009.09.27~2009.09.30, | 2009 . 09 |
48 | (Case discussion) Successful RFA with PEI to one 3.7 cm HCC at S6 tip high risk location,98年度中部地區台灣肝癌醫學教育研討會,彰化基督教醫院11樓連瑪玉講堂,2009.07.11~2009.07.11, | 2009 . 07 |
49 | Peginterferon Alfa and Ribavirin Therapy for 24 versus 48 Weeks in Chronic Hepatitis C Genotype 1 Patients,台灣消化系醫學會 台灣消化系內視鏡醫學會2009年聯合學術演講年會,台北醫學大學,2009.03.14~2009.03.15, | 2009 . 03 |
50 | PEGYLATED INTERFERON α-2A THERAPY FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B,中華民國九十八年消化系聯合學術演講年會,台北醫學大學附設醫院,2009.03.14~2009.03.15, | 2009 . 03 |
專書
暫無資料研究計畫
研究計畫/Research Grant (研究類型,研究計畫代號,主持人,補助或委託單位名稱,計畫名稱,計畫期間) |
日期 | |
1 | 個別型,MOST 109-2314-B-182-062-MY3,高榮達(Jung-Ta Kao)、黃朝錦、林成俊、陳景彥、葉文凌,科技部,整合性飲酒介入方案對於危險性飲酒病人家屬之成效評值,2020.8.1~2021.7.31 | 2020 . 08 |
2 | 臨床試驗與研究計畫,CMUH104-REC1-048,彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、陳景祥、陳政國(Cheng-Kuo Chen)、楊宏仁(Horng-Ren Yang)、陳自諒(Tzu-Liang Chen)、柯道維(Tao-Wei Ke)、王輝明(Hwei-Ming Wang)、廖裕民,附醫廠商計畫,台灣選擇性體內放射療法登錄研究,2018.1.1~2018.12.31 | 2018 . 01 |
3 | 臨床試驗與研究計畫,CMUH104-REC1-048,彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、 陳景祥、陳政國(Cheng-Kuo Chen)、楊宏仁(Horng-Ren Yang)、陳自諒(William Tzu-Liang Chen)、柯道維(TAO-WEI KE)、王輝明(Hwei-Ming Wang)、廖裕民,附醫廠商計畫,台灣選擇性體內放射療法登錄研究,2016.1.1~2016.12.31 | 2016 . 01 |
4 | 整合型項下子計畫(主持人),CMU100-NTU-05,吳怡瑩(WU YI-YING),,探討B型、C型、及非B非C型肝炎患者,其體內抑制性及刺激性免疫分子對肝硬化患者靜脈曲張與肝癌患者預測癒後之影響,2012.8.15~2013.8.14 | 2012 . 08 |
5 | 產學合作,09842720,楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者晚期肝細胞癌之病患,以BRIVANIB或SORAFENIB作為第一線治療之比較(BRISK FL研究)』,2011.7.1~2012.5.31 | 2011 . 07 |
6 | 個別型,CMU99-NTU-09-2,吳怡瑩(WU YI-YING),本校(含附醫),2011_03_15_肝細胞癌誘發細胞凋亡中PD-L1調節訊息傳遞的角色,2011.4.1~2012.3.31 | 2011 . 04 |
7 | 個別型,CMU99-NTU-09-1,,本校(含附醫),T細胞次群與細胞激素在人類慢性肝炎感染引發病灶之角色,2011.4.1~2011.7.31 | 2011 . 04 |
8 | 產學合作,099427E2,賴學洲(Hsueh-Chou Lai)、蘇文邦、高榮達(Jung-Ta Kao),附醫廠商計畫,針對未使用過干擾素,且其B型肝炎病毒e抗原呈陽性的慢性B型肝炎病毒感染病患,評估接受聚乙二醇化干擾素Lambda (BMS-914143)單一藥物治療之安全性、療效和藥物動力學的劑量範圍試驗,2010.11.19~2011.11.18 | 2010 . 11 |
9 | 產學合作,099427C4,彭成元(Cheng-Yuan Peng)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,一項多中心、隨機分配、開放性、平行分組第IIB期試驗,針對未經治療的C型肝炎基因型第二型及第三型患者,單獨使用DEB025口服劑或併用ribavirin與標準照護(peg-IFN α 2a 加上ribavirin)比較其療效性及安全性,2010.9.17~2011.9.16 | 2010 . 09 |
10 | 產學合作,09842721,楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者有晚期肝細胞癌(HCC)但對SORAFENIB治療失敗或不耐受的受試者,施以BRIVANIB加上最佳支持行照顧(BSC)與安慰劑加上最佳支持性照護(BSC)之比較:BRISK PS,2010.9.1~2011.8.31 | 2010 . 09 |
11 | 個別型,DRM-100-018,吳怡瑩(WU YI-YING),附醫院內計畫,肝細胞癌誘發細胞凋亡中PD-L1調節訊息傳遞的角色,2010.8.1~2011.7.31 | 2010 . 08 |
12 | 產學合作,09842720,楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者晚期肝細胞癌之病患,以BRIVANIB或SORAFENIB作為第一線治療之比較(BRISK FL研究)』,2010.7.1~2011.6.30 | 2010 . 07 |
13 | 產學合作,099427B1,楊宏仁(Horng-Ren Yang)、楊美都(Mei-Due Yang)、莊伯恒(Po-Heng Chuang)、彭成元(Cheng-Yuan Peng)、蘇文邦(Wen-Pang Su)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、高榮達(Jung-Ta Kao)、陳永芳(Yung-Fang Chen)、陳德鴻(Te-Hong Chen),附醫廠商計畫,一項臨床第四期、單組、開放性試驗,評估sorafenib(Nexavar蕾莎瓦R)使用於晚期肝細胞腫瘤(肝癌)患者,2010.6.30~2011.6.29 | 2010 . 06 |
14 | 產學合作,M09842760,賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,一項隨機分派、雙盲、安慰劑對照試驗,評估C型肝炎患者在標準併用療法的六個月追蹤期間,經口腔黏膜途徑投予低劑量人類干擾素-Α的療效與安全,2010.4.20~2011.4.19 | 2010 . 04 |
15 | 產學合作,09842794,賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,針對之前未曾接受過核?治療的慢性B型肝炎病患開始在門診接受核?治療的觀察性研究,2010.3.29~2011.3.28 | 2010 . 03 |
16 | 個別型,CMU98-NTU-05,,本校(含附醫),共同抑制性分子和共同刺激性分子在B型肝炎病人中於週邊血液單核球及肝臟浸潤細胞表現之關係,2010.2.1~2011.1.31 | 2010 . 02 |
17 | 個別型,CMU99-NTU-05,吳怡瑩(WU YI-YING),,共同抑制性分子和共同刺激性分子在B型肝炎病人中於週邊血液單核球及肝臟浸潤細胞表現之關係,2010.2.1~2011.1.31 | 2010 . 02 |
18 | 產學合作,09842753,楊宏仁(Horng-Ren Yang)、楊美都(Mei-Due Yang)、莊伯恒(Po-Heng Chuang)、彭成元(Cheng-Yuan Peng)、蘇文邦(Wen-Pang Su)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、高榮達(Jung-Ta Kao)、陳永芳(Yung-Fang Chen),附醫廠商計畫,比較 LINIFANIB(ABT-869)與SPORAFENIB 對晚期肝細胞癌(HCC)病患的療效及耐受性之開放型,隨機,第三期試驗,2009.12.30~2010.12.29 | 2009 . 12 |
19 | 產學合作,09842746,賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,對曾參加其它MK-7009臨床試驗的慢性C型肝炎病毒感染病患,併用MK-7009、長效干擾素(PEGYLATED-INTERFERON ALFA-2A)及RIBAVIRIN的第二期開放型研究,2009.10.21~2010.10.20 | 2009 . 10 |
20 | 產學合作,09842721,楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者有晚期肝細胞癌(HCC)但對SORAFENIB治療失敗或不耐受的受試者,施以BRIVANIB加上最佳支持行照顧(BSC)與安慰劑加上最佳支持性照護(BSC)之比較:BRISK PS,2009.9.1~2010.8.31 | 2009 . 09 |
21 | 產學合作,09842731,楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第III期試驗,以BIVANIB相對於安慰劑作為經動脈化療栓塞術(TACE)之輔助療法,用於無法藉由手術切除肝細胞癌之病患:BRISK TA 試驗,2009.8.13~2010.8.12 | 2009 . 08 |
22 | 產學合作,09842720,楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者晚期肝細胞癌之病患,以BRIVANIB或SORAFENIB作為第一線治療之比較(BRISK FL研究)』,2009.7.1~2010.6.30 | 2009 . 07 |
23 | 產學合作,09742705,賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,在曾接受治療之慢性第1基因型C型肝病毒感染病患評估4種不同MK-7009療方與聚乙二醇化干擾素(PEGYLATED-INTERFERON)及RIBAVIRIN同時使用之安全性耐受性與療效的第二期、隨機分組、安慰劑對對照之研究,2009.6.1~2012.12.31 | 2009 . 06 |